A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
NCT ID: NCT01874288
Last Updated: 2020-11-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
24 participants
INTERVENTIONAL
2013-11-25
2016-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The dose escalation portion of the trial will incorporate a modified accelerated titration design. Therefore, the trial will enroll 3 participants per dose level with a doubling of the dose at each level during the accelerated stage of the study (skipping every other dose level). Once the first instance of any Grade 3 or higher treatment related toxicity (with some notable exceptions) is observed on the first cycle, the accelerated stage will end and the trial will revert to a conventional design using cohorts of 3 or 6 participants (standard 3+3 design), with single step 2 milligrams (mg)/square meter (m\^2) increments.
To further explore the clinical efficacy, additional participants (up to 12 per cohort) may be enrolled at the optimal biologic dose (OBD) or maximum tolerated dose (MTD).
At the end of the study, participants may be enrolled into an open-label extension study (AO-101-EXT \[NCT02151903\]), at the discretion of the investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DI-Leu16-IL2 0.5 mg/m^2
Participants will receive DI-Leu16-IL2 0.5 mg/m\^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
DI-Leu16-IL2 1.0 mg/m^2
Participants will receive DI-Leu16-IL2 1.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
DI-Leu16-IL2 2.0 mg/m^2
Participants will receive DI-Leu16-IL2 2.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
DI-Leu16-IL2 4.0 mg/m^2
Participants will receive DI-Leu16-IL2 4.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
DI-Leu16-IL2 6.0 mg/m^2
Participants will receive DI-Leu16-IL2 6.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DI-Leu16-IL2
DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must have received prior rituximab-containing therapy.
3. Evaluable disease. In the absence of lymphadenopathy, splenomegaly with defects or measurable extra-medullary disease is acceptable.
4. Participants who have received a prior autologous stem cell transplant are eligible if the transplant occurred \>6 months ago.
5. Participants who have received a prior allogeneic stem cell transplant are eligible if:
1. The transplant occurred \>6 months ago
2. There is no evidence of active graft versus host disease
3. Systemic immunosuppressive agents (including corticosteroids) have not been received for at least 8 weeks
6. Karnofsky performance scale ≥70%
7. Life expectancy ≥12 weeks
8. Adequate baseline functions:
1. Serum creatinine ≤1.5 mg/deciliter (dL)
2. Total white blood cell (WBC) count ≥3000/microliter (µL) or absolute neutrophil count (ANC) ≥1000/µL
3. Absolute lymphocyte count ≥0.75 \* 10\^3/µL
4. Platelet count ≥75,000/µL
5. Hematocrit ≥25% or hemoglobin ≥9 grams/100 milliliters (mL)
6. Alanine aminotransferase (ALT) \<2.5 \* upper limit of normal (ULN)
7. Aspartate aminotransferase (AST) \<2.5 \* ULN
8. Total bilirubin (TBili) \<1.5 \* ULN
9. Sodium, potassium, and phosphorus levels no worse than grade 1
10. Chest x-ray (CXR) or computed tomography (CT) within 4 weeks prior to Day 1 with no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or significant emphysema. If results are questionable, participants should have additional lung function testing to exclude clinically relevant restriction or obstruction. Participants must have a forced expiratory volume (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) of at least 65% and 50% of expected, respectively.
11. Electrocardiogram (12-lead ECG) QTc ≤480 millisecond (ms)
12. Cardiac stress test (for example, stress thallium scan, stress echocardiography) with normal results if participant is suspected to have coronary artery disease.
9. Participants participating in the study are to use adequate birth control measures (abstinence, oral contraceptives, barrier method with spermicide or surgical sterilization) during the study. Females of childbearing potential must have a negative serum pregnancy test on the days of dosing. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (that is, has had menses at any time in the preceding 24 consecutive months).
10. Provide written informed consent prior to any screening procedures
Exclusion Criteria
2. Prior treatment with interleukin 2 (IL2) within the last 5 years
3. Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusion of rituximab
4. Pregnant or lactating female
5. An immediate need for palliative radiotherapy or systemic corticosteroid therapy
6. Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions
7. Actively infected with or chronic carriers of hepatitis B virus as demonstrated by positive hepatitis B core antibody or hepatitis B surface antigen. Participants who are seropositive only, that is, surface antibody positive \[HbsAb\], are permitted.
8. Other significant active infection.
9. Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day 1
10. Uncontrolled hypertension (diastolic greater to or equal to 100 millimeters of mercury \[mmHg\]) or hypotension (systolic less than or equal to 90 mmHg)
11. History of repeated and clinically relevant episodes of syncope or other paroxysmal, ventricular, or other significant arrhythmias
12. History of medically significant ascites requiring repetitive paracentesis
13. Previous diagnosis of autoimmune disease (Exceptions: participants with autoimmune thyroiditis or vitiligo may be enrolled)
14. Organ transplant recipient
15. History of prior therapy or a serious, uncontrolled medical disorder that in the Investigator's opinion would impair participation in the study
16. Known hypersensitivity to Tween-80 or human immunoglobulin
17. Legal incapacity or limited legal capacity
18. Participants with bulky lymph nodes (LNs) (≥10 centimeters \[cm\]) or marked splenomegaly (that is, extending into pelvis or crossing the midline).
19. Circulating levels of rituximab \>75.0 micrograms (µg)/mL
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alopexx Oncology, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Vlock, MD
Role: STUDY_DIRECTOR
Alopexx Oncology, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
St. Jude Hospital Yorba Linda
Fullerton, California, United States
University of Minnesota
Minneapolis, Minnesota, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Joe Arlington Cancer Research and Treatment Center
Lubbock, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15;22(22):4463-73. doi: 10.1200/JCO.2004.11.035. Epub 2004 Oct 13.
Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun;27(3):232-9. doi: 10.1097/00002371-200405000-00008.
Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor website
National Cancer Institute at the National Institute of Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AO-101
Identifier Type: -
Identifier Source: org_study_id